Brainomix 360 e-CTA vs Etiometry

Etiometry emphasizes a user-friendly interface that aggregates and visualizes real-time data from various sources into a single, easy-to-interpret display, aiming to reduce cognitive load for clinicians. It also offers EHR-embedded access via SMART-on-FHIR, allowing clinicians to view data without leaving their normal workflow. Brainomix 360 e-CTA offers a mobile app and web UI for viewing results and coordinating care, but Etiometry's focus on reducing cognitive load and seamless EHR integration suggests a slightly stronger emphasis on day-to-day usability in a high-acuity environment.

Etiometry's platform provides deep physiologic insights, FDA-cleared risk analytics (IDO2, IVCO2, ACD, HLA), and supports automation of hospital-defined clinical pathways, leading to documented reductions in ICU length of stay, readmissions, and ventilation time. Brainomix 360 e-CTA focuses on automated collateral assessment and LVO detection for acute stroke, with studies showing rapid and reliable analysis. While both offer clinical value, Etiometry's broader impact across various critical care outcomes and its ability to automate clinical pathways for standardized care give it an edge in overall clinical value.

Both companies state that pricing information is available upon contacting the vendor, indicating a lack of public transparency. Without specific pricing details or case studies directly comparing cost-effectiveness, it is not possible to definitively determine which tool offers better pricing and value. Both platforms aim to improve patient outcomes and efficiency, which can lead to cost savings, but the exact return on investment for each remains undisclosed.

Etiometry demonstrates strong enterprise readiness through its hybrid deployment options, HIPAA compliance, and proven integrations with EHRs and various medical devices. It supports a unified view of patient data across critical care environments and step-down units, and its implementation process is described as straightforward with minimal IT support required. Brainomix 360 e-CTA also offers cloud and on-site deployment, HIPAA compliance, and DICOM integration, but Etiometry's extensive focus on aggregating data from disparate systems and its track record of enterprise agreements across various ICU segments suggest a more comprehensive enterprise solution.

Etiometry showcases innovation through its FDA-cleared risk analytics that provide real-time insights for early deterioration identification and its Algorithm Development Kit (ADK 2.0) which empowers clinician researchers to develop custom algorithms. The platform's continuous integration of high-resolution waveform data also offers deeper insights into patient physiology. Brainomix 360 e-CTA's innovation lies in its automated collateral assessment and LVO detection, and its ability to estimate ischemic core volumes from non-contrast CT scans. However, Etiometry's broader application of AI for predictive analytics across diverse physiological data and its support for custom algorithm development suggest a slightly higher degree of innovation.

Etiometry provides comprehensive support, including super user sessions, end-user training, help desk education, ongoing clinical meetings, and continuous education after launch. Their implementation process is described as efficient with ongoing adoption programs. Brainomix offers user manuals, FAQs, and contact information for support. While both provide documentation and support, Etiometry's detailed training and ongoing educational initiatives, coupled with positive feedback on their responsiveness, indicate a more robust support system.